METHODS:
We performed a retrospective analysis of colorectal tumor samples collected from 1995 patients at 22 hospitals in Germany, between 2003 and 2010. Samples were analyzed for MSI-H using an established mononucleotide marker panel; BRAF mutations (BRAFV600E) were detected by Sanger sequencing or in tissue microarray blocks using immunohistochemistry. Cancers were assigned to categories of having MSS without mutations in BRAF, MSS with mutant BRAF, MSI-H without mutations in BRAF, and MSI-H with mutant BRAF. We investigated the association between tumor categories with clinical and pathologic features and patient's overall, disease-specific, and recurrence-free survival (median follow-up time, 5.1 y).
RESULTS:
Tumors were stage I in 364 (18%), stage II in 678 (34%), stage III in 673 (34%), and stage IV (14%) in 280 patients. Sixty-three percent of tumors were located in the colon and 37% in the rectum. Most tumors (85%) had MSS without mutations in BRAF, 3% had MSS with mutant BRAF, 7% had MSI-H without mutations in BRAF, and 5% had MSI-H with mutant BRAF. In patients whose tumors were MSI-H, mutation of BRAF did not significantly affect survival time.
Patients whose tumors had MSS with mutant BRAF had significantly reduced overall survival (hazard ratio [HR], 2.16; 95% CI, 1.54-3.04; P < .001), disease-specific survival (HR, 2.59; 95% CI, 1.77-3.79; P < .001), and recurrence-free survival (HR, 2.45; 95% CI, 1.70-3.52; P < .001) than patients whose tumors had MSS without BRAF mutation. Although BRAF mutations in tumors with MSS were associated with disease-specific survival of patients with stage III or IV tumors (P < .001), these features did not affect survival of patients with stage II tumors (P [ .639).
See editorial on page 391; see related article on page 402.
C olorectal cancer (CRC) is a heterogeneous disease, comprising different genetic and molecular characteristics. Prognosis is determined mainly by tumor stage; however, molecular markers, such as microsatellite instability (MSI), BRAF, and KRAS have shown differential associations with survival. 1, 2 BRAF is an intracellular component of the mitogenactivated protein kinase pathway located downstream of epidermal growth factor receptors and RAS molecules. 3, 4 The mutational activation of BRAF, mainly through a missense mutation at codon 600 (V600E), constitutively activates mitogen-activated protein kinase signaling and is found in a variety of malignant and benign tumors, including CRC (w10%) [5] [6] [7] and sessile serrated lesions (w70%). 8, 9 Remnants of sessile serrated lesions at the mucosal surface of BRAF mutated (BRAFmut) cancer suggest that these mutations induce adenoma development rather than causing the malignant transformation of an adenoma. 10 According to the well-established serrated pathway theory of CRC, the BRAF mutated sessile serrated lesion precursor may transform into cancer by either additive methylation-induced silencing of MLH1 and consecutive microsatellite instability-high status (MSI-H/BRAFmut), or by additive mutations in gate keeper genes (mainly p53) resulting in a MSS/BRAFmut constellation. 11, 12 According to international guidelines, adjuvant chemotherapy for CRC is restricted to stages III and IV. Adjuvant therapy also should be considered in stage II when risk factors such as a low number of investigated lymph nodes (<12), emergency surgical resection, highgrade conventional histology in microsatellite-stable (MSS) tumors, lymphatic invasion, or tumorous penetration of the serosa and/or infiltration of adjacent organs are present. 13, 14 Despite the identification of these risk factors, cancer-related deaths of patients with stage II cancers still occur in approximately 10% of cases. 15 Whether molecular pathologic factors are able to identify patients at risk in stage II and whether these patients would benefit from adjuvant chemotherapy is a major point of oncologic research and discussion.
Numerous previous studies have shown an association of BRAF mutations and adverse outcomes in CRC. [16] [17] [18] [19] Although the data are consistent for MSS cancers, results on MSI-H carcinomas with BRAF mutations are conflicting. 18, 20 MSI-H cancers usually show a better outcome compared with MSS cancers and the main body of studies have indicated that BRAF mutations in combination with MSI-H do not influence prognosis whereas the combination of a BRAF mutation with MSS cancers is a predictor of adverse outcome. [20] [21] [22] Therefore, combined testing for BRAF mutations and MSI-H may hold potential in identifying patients with stage II cancers at higher risk for tumor-associated death. The aim of this study was to evaluate the association of combined MSI-BRAF status with patient survival according to stage at diagnosis.
Methods

Study Design
The Darmkrebs: Chancen der Verhütung durch Screening study is an ongoing population-based, casecontrol study on CRC in the Rhein-Neckar region in Germany with long-term follow-up evaluation of patients. For this analysis we used information from the patients only (patient cohort study) with available information on MSI, BRAF, and long-term follow-up evaluation. Details of the study design have been reported previously. 23 In brief, patients with histologically confirmed diagnosis of CRC, age older than 30 years, and ability to participate in an interview were eligible for inclusion. Between 2003 and 2010, patients were recruited in 22 hospitals of the study region offering treatment for CRC. Tumor tissue samples were requested from Pathology Institutes associated with the clinics. Patients with missing marker data owing to a lack of available tumor tissue or owing to testing failure were excluded from the analysis.
At baseline, data on sociodemographic characteristics, family and medical history, and symptoms of the disease were collected by trained interviewers using a standardized questionnaire. Medical and pathology reports were checked for information including stage of disease and pathologic characteristics of the tumor. Follow-up evaluation was performed at 3 years after diagnosis, and included information on the type of therapy received for the treatment of CRC, recurrence of disease, comorbidities, and vital status. Further followup evaluation at 5 years after diagnosis included an update on recurrence of disease, treatment, comorbidities, and vital status. Vital status, date, and cause of death were determined using data from the population registries and from death certificates collected from the health authorities.
Molecular Marker Characterization
Tumor tissue analyses were performed on formalinfixed, paraffin-embedded (FFPE) samples (Supplementary methods).
Statistical Analysis
Patients were categorized into 1 of 4 subtypes depending on their MSS and BRAF status (MSS/BRAFnon-mut, MSS/BRAFmut, MSI/BRAFnon-mut, and MSI/ BRAFmut). The distribution of demographic and clinical characteristics was analyzed according to the MSI/BRAF status group, using the chi-square test to investigate heterogeneity of distributions in relation to the most common subtype (MSS/BRAFnon-mut). Associations between molecular subtypes and disease-specific survival (DSS), recurrence-free survival (RFS), and overall survival (OS) were evaluated using Cox proportional hazards regression adjusting for age, sex, stage of disease, location of the tumor, chemotherapy, timedependent effects of chemotherapy and age, and delayed entry into the study. Stratified analyses and tests for interactions were performed by stage of the disease and by location of the tumor. We plotted both direct adjusted and Kaplan-Meier survival curves for each subtype for early and late-stage CRC. All analyses were performed using SAS version 9.4 (SAS Institute, Inc, Cary, NC). We conducted a meta-analysis to compare and combine our results with those previously published by other investigators (Supplementary methods).
Results
Patient Characteristics
Of 2036 patients, those with missing information on tumor stage (n ¼ 37) were excluded from this analysis. 
Findings
Patients with microsatellite stability/BRAF-mutated tumors had significantly reduced overall, diseasespecific and recurrence-free survival compared to those with microsatellite stability/BRAF nonmutated tumors. This association was not significant for patients with early-stage tumors.
Implications for patient care
These findings support the use of BRAF mutational testing for risk assessment in stages III and IV but not in stages I and II.
Also, patients who died within the first month after diagnosis were excluded (n ¼ 4) because the cause of death was considered to result from cancer treatment (ie, surgery). 24 Characteristics of the 1995 included patients are presented in Table 1 . Overall, 891 patients received adjuvant chemotherapy (18% stage II, 79% stage III, and 85% stage IV patients). Eighty-five percent of the patients had MSS/BRAFnon-mut CRC, 3% had MSS/BRAFmut, 7% had MSI-H/BRAFnon-mut, and 5% had MSI-H/BRAFmut tumors. BRAFmut cancers, irrespective of microsatellite status, were associated with female sex, location in the proximal colon, and poor differentiation. The most obvious differences between the 4 cancer categories were related to stage distribution: although MSS/BRAFnon-mut tumors were distributed equally among early (I-II) and advanced (III-IV) stages, MSS/BRAFmut cancers were more common in advanced stages (68.7%). MSI-H cancers with and without BRAF mutation were significantly more common in early stages (67.7% and 71.7%, respectively) ( Table 1 and Figure 1 ).
Survival by Microsatellite Stability/BRAF Status
In the survival analyses, the median follow-up time was 5.1 years. In total, 649 patients died during the follow-up evaluation (32.5%), of whom 431 (66%) died of CRC. Supplementary Figure 1) .
In an analysis stratifying by location of the tumor, the association of the MSS/BRAFmut subtype compared with the MSS/BRAFnon-mut was stronger for the distal colon/rectum stratum (HR, 3.57; 95% CI, 1.9-6.6) than for the proximal colon stratum (HR, 1.89; 95% CI, 1.2-3.1); however, a test for interaction was not statistically significant (P ¼ .274) (Supplementary Table 2 ). Table 4 presents a summary of the meta-analysis results from 9 publications on MSI/BRAF status and survival 20, 22, [25] [26] [27] [28] [29] [30] [31] (see Supplementary Table 3; and Supplementary Figures 2, 3 for details) .
Meta-Analysis of Results
Discussion
In the present study, we applied combined testing for MSI-H and BRAF mutations in tumors of 1995 CRC patients from a population-based study to categorize them into 4 subgroups. In line with the results of previous studies, 32, 33 we observed overlaps in clinicopathologic characteristics in the 2 BRAF mutated groups. Both MSI-H and MSS carcinomas with BRAF mutations showed preferential location in the right colon, poor differentiation, and female predominance (P < .001 each). These data are in accordance with the canonical serrated pathway theory in which BRAF mutated colon cancers, irrespective of their microsatellite status, share a common origin in the sessile serrated lesion. Sessile serrated lesions show BRAF mutations in 60% to 90% of cases, 34, 35 and a previous analysis showed that adenoma remnants of both MSI-H and MSS cancers already are BRAF mutated and show crypt serration. 36 Thus, BRAF mutation is a mechanism of precursor development and does not seem to play a critical role in the step of malignant transformation.
Contrary to the similarities in gender distribution and tumor location, MSI-H/BRAFmut and MSS/BRAFmut cancers were found to differ significantly in their biologic behavior. By using the most common MSS/BRAFnon-mut group as a reference, disease-specific survival was rather favorable in the MSI-H/BRAFmut and poorest for the MSS/BRAF group (Figure 1 ), this result also was observed in the meta-analysis (Table 4) . A previous systematic review summarizing molecular classifications based on at least 3 markers also indicated that subtypes defined by MSS and either BRAF or KRAS mutations showed worse survival patterns compared with the nonmutated subtypes. 37 Although for MSI-H cancers the presence of a BRAF mutation had no prognostic effect, the presence of a BRAF mutation in MSS cancers was associated strongly with a poorer prognosis. Our data are well in line with the survival results of combinational CRC analyses presented by 2 larger previous studies. 21, 26 Given the lack of association of BRAF mutations with adverse outcome in MSI-H cancers, these data may indicate that BRAF mutations per se are not an indicator of adverse outcome. The oncogenic effect of BRAF mutations may be decreased when a strong immunologic host response typically seen in MSI-H cancers is present. 38 It also is possible, however, that a BRAF mutation is a marker of an aggressive cancer type, but does not play a causative role for aggressive tumor behavior.
The 4 subgroups defined by MSI and BRAF mutation showed a different distribution of International Union for Cancer Control cancer stages. Although the most common cancer type defined by the combination of MSS/BRAFnonmut showed an almost equal distribution between early and advanced stages, MSS/BRAFmut cancers were associated strongly with advanced stages. In contrast, MSI-H cancers, independently of a BRAF mutation, were associated predominantly with early stages. Consequently, the proportion of MSS/BRAFmut cancers increased with increasing cancer stage (1.9% stage I to 8% stage IV), whereas the share of MSI-H/BRAFmut cancers decreased with increasing stage (4% stage I to 0.3% stage IV).
To investigate differences in disease-specific survival, which were independent of the different stage distributions among the 4 subtypes, the association with clinical outcome was examined for each cancer stage. By this approach we found a stage III and IV specific association of the MSS/BRAFmut cancer type with survival. The association also was independent of the number of tumorpositive lymph nodes in stage III (pN1 vs pN2; data not shown) and was not influenced significantly by adjuvant chemotherapy, indicating that BRAF mutations are common in aggressive types of CRC and lack significant response to conventional adjuvant chemotherapy. Despite the results in advanced stages, no evidence was observed for adverse outcome of MSS/BRAFmut cancers in stage II patients, and no events were observed in stage I patients. These somewhat surprising data, however, are in line with a study by Phipps et al, 20 which reported only a single cancer-related death among 91 patients with localized BRAF mutated cancers. This Surveillance, Epidemiology, and End Results Program-defined group of localized cancer translates into International Union for Cancer Control stages I and II, except for advanced stage II cancers, which either penetrate the serosa or extend to different organs. 39 Phipps et al 20 did not explicitly report the MSI status of the localized BRAF mutated cancers but given the similar distribution of MSS and MSI-H cancers in their study (46% MSS/BRAFmut vs 40% in our study), we assume that at least 10 stage II MSS/BRAFmut cancers were among the 91 cases. Lacking impact on RFS of MSS/BRAFmut also was reported for stage II cancers of the Pan-European Trials in Alimentary Tract Cancers -3 (PETACC3) trial, although these data may not be comparable with our stage II cancers because all stage II patients of the PETACC3 trial received adjuvant therapy. 22 Other studies suggested a role of BRAF and combinational BRAF/MSI testing in earlier cancer stages, but only a few very small studies have specifically addressed stage II. Fariña-Sarasqueta et al 40 reported poorer survival among 6 patients with MSS/BRAFmut, but only reported event numbers not differentiating between MSS and MSI-H cancers in stage II. Similarly, Seppälä et al 31 observed adverse an outcome in 3 of 9 MSS/BRAFmut stage I to II patients, whereas Samowitz et al 16 reported cancer-related death in 3 of 6 patients with MSS/BRAFmut stage II cancers. Previous studies including patients with stage III CRC have found that survival after recurrence of cancer was worse among those with BRAFV600E than among those without. 29, 30 It is possible, therefore, that stage II BRAF mutated cancers also might show a poorer treatment response or a poorer prognosis once they recur.
We used BRAFV600E immunohistochemistry and DNA sequencing to detect BRAF mutations in tumor tissue. Both approaches yielded highly similar results concerning the mutational frequencies and the associations with clinicopathologic factors in our study. As previously reported, BRAFV600E immunohistochemistry requires optimized staining protocols. 41 In the present study, we used the same antibody dilutions and identical conditions that showed a sensitivity of 100% and a specificity of 98.8% in a previous study on CRC. 42 In contrast, 1 study comparing immunohistochemistry and sequencing using the VE1 antibody for BRAFV600E detection in CRC found significant discordance. 43 Most studies that provide stage-specific information for patient survival have been performed based on cohorts from clinical trials, and may not be comparable with results obtained from population-based studies. In addition, cohort studies have reported DSS for patients of all stages, and few provide stage-specific information, mostly limited by very small numbers of patients with molecular marker information in early stages. In this analysis we provide further evidence of poorer diseasespecific survival for MSS/BRAFmut tumors in stage III to IV patients. The lack of association with disease-specific survival in stage I to II patients should be interpreted cautiously because despite the overall large size, the study was not powered sufficiently to assess associations with survival in this subgroup. Furthermore, with the low number of events, Cox regression analyses can be biased when adjusting for multiple covariables. However, our analysis presents a cohort of unselected patients, in which no selection based on age or treatment was performed, allowing for better generalizability of results, in contrast to those obtained from selected patients included in clinical trials.
To conclude, a BRAF mutation is common in a biologic variant of MSS CRC characterized by preferential location in the right colon, advanced cancer stage at the time of diagnosis, and poor survival. The absence of an association of a BRAF mutation with adverse outcome in MSI-H cancers, however, indicates that BRAF mutations are not necessarily causative for the aggressive biology. Data on the relevance of MSS/BRAFmut in stage II are limited and the few analyses on the topic reported to date are conflicting. In this analysis we could not confirm a role of MSS/BRAFmut as a risk factor for poorer prognosis in stage II CRC. This should be studied in further analyses with larger numbers of stage II patients to obtain more conclusive results.
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Note: To access the supplementary material accompanying this article, visit the online version of Clinical Gastroenterology and Hepatology at www.cghjournal.org, and at https://doi.org/10.1016/j.cgh.2018.04.015. compared with the MSS/ BRAFnon-mut group. Four studies [9] [10] [11] [12] provided information from cohorts of stage III patients recruited in 3 clinical trials, in which both DSS and OS were poorer for the MSS/BRAFmut subtype. Other reported outcomes in these trials, such as survival after relapse and time to recurrence, also showed significantly worse survival for the MSS/BRAF mutated subtype. [9] [10] [11] [12] Supplementary References Figure  3 . Overall and disease-free survival (stage III). 
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